The pharmaceutical industry could generate more than $1.2 trillion in global sales in 2025, according to Statista. The cancer segment alone is expected to generate $208 billion in sales this year. The ...

Next up, Tremfya made a triumphant return to the 2024 roundup after falling off the rankings in 2023. The med's return came ...

MoonLake Immunotherapeutics, a clinical-stage biotech firm valued at $2.6 billion, is generating excitement with its ...

Skyrizi was the top Rx and over-the-counter (OTC) pharma brand advertising on TV in 2024, according to data released by iSpot.tv on Thursday afternoon. AbbVie’s psoriasis, ulcerative colitis, Crohn’s ...

In the last four months of 2024, the FDA tacked on nods for Bimzelx to treat psoriatic arthritis ... 12:55 p.m. ET The remarkable success of Skyrizi and Rinvoq has allowed AbbVie to accomplish ...

Skyrizi is an effective treatment option for plaque psoriasis, Crohn’s disease, ulcerative colitis, and psoriatic arthritis. Success rates may vary depending on the condition being treated and ...

The emergence of new treatments and therapeutic approaches for psoriatic arthritis is improving physicians’ ability to treat a complicated, multifaceted disease. This episode details how ...